SAN DIEGO–(BUSINESS WIRE)—- $ARCT #65Roses–Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will host a virtual presentation on Wednesday, September 23, 2026, at 4:30 p.m. ET. The presentation will provide an overview of the ARCT-810 Phase 2 clinical program for Ornithine transcarbamylase (OTC) deficiency and Arcturus’ mRNA liver therapeutics pl
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
